Bacteria in Crohn's disease: Mechanisms of inflammation and therapeutic implications

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 1, 2007, Pages

  Balfour Sartor, R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Crohn's; Organisms

Indexed keywords

BACTERIAL FLORA; BACTERICIDAL ACTIVITY; BACTERIUM; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES VULGATUS; BIFIDOBACTERIUM; CELLULAR IMMUNITY; CROHN DISEASE; DIET; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FUSOBACTERIUM VARIUM; GENETIC SUSCEPTIBILITY; HELICOBACTER; HUMAN; HYGIENE; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RESISTANCE; INFECTION SENSITIVITY; INFLAMMATION; KLEBSIELLA PNEUMONIAE; LACTOBACILLUS; MUCOSAL IMMUNITY; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES BOULARDII;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROHN DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; INTESTINAL MUCOSA;

EID: 34247243350     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31802db364     Document Type: Review

References (45)

1. Wilson KH. Natural biota of the human gastrointestinal tract. In: Blaser MJ, Smith PD, Ravdin JI, et al. eds. Infections of the Gastrointestinal Tract. Philadelphia: Lippincott Williams & Wilkins; 2002.
2. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355-1359.
3. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-1638.
4. Sartor RB. Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor RB, Sandborn WJ, eds. Kirsner's Inflammatory Bowel Diseases. Edinborough: Elsevier Publishers; 2004.
5. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
6. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease? Gut. 2005;54:896-898.
7. Lund BM, Gould GW, Rampling AM. Pasteurization of milk and the heat resistance of Mycobacterium avium subsp. paratuberculosis: a critical review of the data. Int J Food Microbiol. 2002;77:135-145.
8. Mishina D, Katsel P, Brown ST, et al. On the etiology of Crohn disease. Proc Natl Acad Sci U S A. 1996;93:9816-9820.
9. Naser SA, Schwartz D, Shafran I. Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn's disease patients. Am J Gastroenterol. 2000;95:1094-1095.
10. Naser SA, Ghobrial G, Romero C, et al. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet. 2004;364:1039-1044.
11. Lerner A, Eluri S, Perl D, et al. Bacterial-aluminum interactions. The role of aluminum in bacterial-induced colitis in IL-10 deficient mice. Gastroenterology. 2006;130:A362.
12. Tsang J, Sartor RB. Effect of diet on colitis in IL-10-/- mice. Gastroenterology. 2005;128:A210.
13. Lee K, Sartor RB. A high sucrose diet exacerbates immune-mediated colitis in IL-10 deficient mice. Gastroenterology. 2006;130:A350.
14. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology. 2004;126:1620-1633.
15. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opinion Gastroenterol. 2005;21:44-50.
16. Moeser AJ, Nighot PK, Ryan KA, et al. Prostaglandin-mediated inhibition of Na+/H+ exchanger isoform 2 stimulates recovery of barrier function in ischemia-injured intestine. Am J Physiol Gastrointest Liver Physiol. 2006;291:G885-G894.
17. Karrasch T, Steinbrecher KA, Allard B, et al. Wound-induced p38 MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol. 2006;207:809-815.
18. Schreiber S, Rosenstiel P, Albrecht M, et al. Genetics of Crohn's disease, an archetypal inflammatory barrier disease. Nat Rev Genet. 2005;6:376-388.
19. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an anti-bacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124:993-1000.
20. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A. 2005;102:18129-18134.
21. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004;5:800-808.
22. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology. 2003;125:47-57.
23. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
24. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731-734.
25. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448-455.
26. Hansen J, Sartor RB. Insights Provided by Animal Models into the Pathogenesis and Treatment of IBD. IBD Yearbook 2006. Toronto: Remedica Medical Publishing; In press.
27. Strober W, Fuss IJ. Experimental models of mucosal inflammation. Adv Exp Med Biol. 2006;579:55-97.
28. Itoh J, de La MC, Strong SA, et al. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut. 2001;49:35-41.
29. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564.
30. Liu Y, Van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology. 1995;108:1396-1404.
31. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
32. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
33. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224-5231.
34. Kim SC, Tonkonogy SL, Albright CA, et al. Different host genetic backgrounds determine disease phenotypes induced by selective bacterial colonization. Gastroenterology. 2005;128:A512.
35. Kim SC, Tonkonogy SL, Bower M, et al. Dual-association of gnotobiotic IL-10-/- mice with two nonpathogenic commensal bacterial species accelerates colitis. Gastroenterology. 2004;126:A291.
36. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest. 2004;113:1296-1306.
37. Strober W, Murray PJ, Kitani A, et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6:9-20.
38. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
39. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
40. Cong Y, Weaver CT, Lazenby A, et al. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J Immunol. 2002;169:6112-6119.
41. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071-1075.
42. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002;123:33-40.
43. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a doubleblind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
44. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623.
45. Dieleman LA, Goerres M, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut. 2003;52:370-376.